-
Anticoagulation with vitamin k antagonists is the standard recommendation for patients with nonvalvular atrial fibrillation and risk factors for stroke. The benefits of warfarin in such patients have been well shown in many clinical trials. Therapy with warfarin, however, is often complicated by the dietary and drug interactions, so that even with frequent monitoring, precise control of the anticoagulation level is difficult.
-
-
It remains debatable as to whether individuals who present with a non-ST-segment elevation MI (NSTEMI) or acute coronary syndrome (ACS) should be managed with a selective or elective invasive strategy vs an approach performing angiography in all patients.
-
In this study, goldenberg and colleagues from the MADIT-II study analyzed risk factors for mortality in that trial. MADIT-II was a randomized trial of ICD versus conventional therapy, which included 1232 patients with documented previous myocardial infarctions who had an ejection fraction of ≤ 30%.
-
Stop smoking drug Chantix rates stronger warning from FDA; Type 2 diabetes surgery on the way?; Vytorin study inconclusive; Influenza A virus found resistant to Tamiflu; FDA actions.
-
This paper gives the results of the substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia (SMASH-VT) study. This study was designed to test the hypothesis that early prophylactic catheter ablation in patients with implantable cardioverter defibrillators (ICD) would decrease the frequency of ICD shocks during follow-up.
-
This remarkable study is a population analysis of a huge cohort of children in Denmark who were followed, since 1930 or later, for the presence of coronary heart disease (CHD), and had all mandatory annual examinations at schools in Copenhagen.
-
-
An early invasive approach is preferred for higher risk non-ST elevation acute coronary syndromes (NSTE-ACS), but the optimal timing of cardiac catheterization is not clear.
-
Doyle and colleagues performed a retrospective study of a large cohort of patients undergoing PCI at the Mayo Clinic from 1994 to 2000, to determine the long-term outcomes of BMS, with a focus on stent thrombosis and ISR.
